Highlight
This first-in-human Phase 1 clinical trial evaluated AHB-137, a novel unconjugated antisense oligonucleotide (ASO) targeting a conserved region near the 3′ end of HBV mRNA, in healthy subjects and patients with chronic hepatitis B (CHB). The study demonstrated that AHB-137 is well tolerated with mostly mild adverse events, exhibits predictable pharmacokinetics including rapid absorption and a long half-life, and induces rapid and sustained reductions in hepatitis B surface antigen (HBsAg), a key marker of viral activity.
